COMMUNIQUÉS West-GlobeNewswire

Oncotelic and Sapu Nano Unveils Broad-Applicability Deciparticle™ Nanomedicine Platform Capable of Formulating Multiple Hydrophobic Peptide, Macrolide, and Polyketide Drugs
02/12/2025
AGOURA HILLS, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% owned Joint Venture, Sapu Nano , a clinical-stage nanomedicine company, today announced new data demonstrating that [...]
Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
02/12/2025
DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos [...]
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology
02/12/2025
— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration Trial — TEL AVIV, Israel, Dec. 02, [...]
Precision Neuroscience Recognized for Innovation and Responsible Technology with Two Industry Awards
02/12/2025
NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision™) a leader in brain–computer interface (BCI) technology, has been named to Inc. Magazine’s 2025 Best in Business list in the Best [...]
SciSparc: Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
02/12/2025
TEL AVIV, Israel, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company [...]
INVO Fertility Announces Pricing of $4.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules
02/12/2025
SARASOTA, Fla., Dec. 02, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (“INVO” or the “Company”) (NASDAQ: IVF), a healthcare company focused on the fertility market, today announced that it has entered into a securities [...]
Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201
02/12/2025
Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel’s advancement across large unmet-need global markets PHOENIX, Dec. 02, 2025 (GLOBE [...]
Longeveron Granted Canadian Patent for Method of Using Stem Cells to Treat Non-Ischemic Dilated Cardiomyopathy and Aging-related Frailty in Patients with Inflammaging
02/12/2025
The patent relates to methods of administering therapeutically effective amounts of isolated allogeneic mesenchymal stem cells (MSCs) to patients with aging-related frailty with inflammaging and also to treat patients [...]
BetaGlue Therapeutics Expands its Clinical Trial in Italy after obtaining from the Italian Ministry of Health Approval to conduct its clinical study in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)
02/12/2025
MILAN, Dec. 02, 2025 (GLOBE NEWSWIRE) -- BetaGlue ® Therapeutics (“BetaGlue” or the “Company”) a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted [...]
ADARx Pharmaceuticals Appoints Mary Tagliaferri, M.D., to its Board of Directors
02/12/2025
– Dr. Tagliaferri is a proven executive recognized for advancing innovative therapies across immunology, oncology and other serious diseases – SAN DIEGO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. ( [...]
Aeroflow Health Celebrates Giving Tuesday Through Donations to Western North Carolina Organizations
02/12/2025
Aeroflow donates several thousand dollars across seven local organizations based in its home state ASHEVILLE, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Aeroflow Health , a pioneering healthcare company that leverages [...]
Reema Health Tackles Medicaid Challenges with $19M Series B from LRVHealth and Optum Ventures
02/12/2025
Engagement Model Blending Humans and Technology Drives 3X ROI to Medicaid MCOs MINNEAPOLIS, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Reema Health , the human powered and tech-enabled solution that engages hard-to-reach members [...]
Alpha Tau Receives FDA Approval to Initiate a Trial for Patients with Locally Recurrent Prostate Cancer
02/12/2025
- FDA approval marks Alpha Tau’s fifth simultaneous active U.S. IDE as the Company expands Alpha DaRT’s reach into recurrent prostate cancer - JERUSALEM, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ [...]
Citizen Health Joins Forces with UCB to Accelerate Drug Development across Epilepsy and Rare Diseases
02/12/2025
The multi-year partnership launches with focus on epilepsy, rare disease and AI SAN FRANCISCO and ATLANTA, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Citizen Health today announced a new strategic partnership with UCB, a global [...]
Orbus Therapeutics Announces Publication of Phase 3 STELLAR Clinical Study Results Showing Clinically Meaningful Improvements in Rare Brain Tumor in Journal of Clinical Oncology (JCO)
02/12/2025
– Eflornithine and lomustine combination doubled progression free survival (PFS) and improved overall survival (OS) in patients with recurrent Grade 3 astrocytoma – PALO ALTO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- [...]
Season Health and Albertsons Companies Launch Community Supports Service in California
02/12/2025
Eligible Medi-Cal members in Contra Costa County can now receive medically tailored grocery bundles from Safeway stores SAN FRANCISCO, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Season Health , a leading clinical nutrition [...]
Ventyx Provides Clinical and Corporate Updates
02/12/2025
Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical Advisor Expanding the Phase 2 recurrent pericarditis study into Canada, EU and the UK to evaluate QD [...]
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
02/12/2025
– Study, Which Enrolled 27 Patients, Met Primary Endpoint with a Significant Reduction in Hearing Loss in 3-18 Year Old Patients who Received PEDMARK ® when Compared with Historically Reported Rates of Hearing Loss in [...]
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
02/12/2025
1st of two presentations with results from Phase 2b study of neflamapimod at the 18 th Clinical Trials on Alzheimer's Disease (CTAD) Conference Data demonstrates neflamapimod treatment led to significant reductions in [...]

Pages